Alkermes Plc (ALKS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
47
About the Report
About the Report
Summary
Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. The company's proprietary products include Aristada, an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, the only once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants license under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to wholesalers, specialty distributors and specialty pharmacies. The company also has a clinical pipeline of products that address CNS disorders such as multiple sclerosis, schizophrenia, depression and addiction. Alkermes is headquartered in Dublin, Ireland.
Alkermes Plc (ALKS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Alkermes Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alkermes Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Alkermes Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alkermes Plc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Civitas Therapeutics Raises USD55 Million in Series C Financing 11
Partnerships 13
Reset Therapeutics Enters into Co-Development Agreement with Alkermes 13
Licensing Agreements 14
Biogen Enters into Licensing Agreement with Alkermes 14
Alkermes Enters into Licensing Agreement with Domain Therapeutics 15
Asset Transactions 16
Recro Pharma Acquires Certain Assets from Alkermes 16
Alkermes Plc-Key Competitors 18
Alkermes Plc-Key Employees 19
Alkermes Plc-Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 23
Financial Announcements 23
Oct 23, 2018: Alkermes announces third quarter 2018 financial results 23
Apr 26, 2018: Alkermes Plc Reports First Quarter 2018 Financial Results 25
Feb 14, 2018: Alkermes Reports Q4 2017 Financial Results 27
Oct 26, 2017: Alkermes Reports Third Quarter 2017 Financial Results 29
Jul 27, 2017: Alkermes Reports Second Quarter 2017 Financial Results 31
Apr 27, 2017: Alkermes Reports First Quarter 2017 Financial Results 32
Feb 15, 2017: Alkermes Reports Financial Results for the Year Ended Dec. 31, 2016 and Provides Financial Expectations for 2017 33
Corporate Communications 35
Mar 01, 2018: Alkermes Names James Robinson as President and Chief Operating Officer 35
Feb 14, 2018: Alkermes Names Shane Cooke As Board Director 36
May 30, 2017: Alkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President, Clinical Development and Medical Affairs 37
Government and Public Interest 38
Oct 26, 2018: Alkermes announces recipients of 3rd Annual ALKERMES INSPIRATION GRANTS 38
Sep 05, 2018: ALKERMES inspiration grants program will award Up to USD 1 Million for the development or expansion of innovative programs 39
Nov 09, 2017: Alkermes Reveals Recipients of the 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders 40
Nov 09, 2017: Alkermes Calls for Impartial National Review of Scientific Data Supporting the Use of FDA-Approved Treatment Options for Opioid Dependence 41
Sep 06, 2017: Alkermes Announces 2nd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders 42
Clinical Trials 43
Jun 29, 2017: Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia 43
Jun 08, 2017: Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients 45
May 01, 2017: Alkermes Announces Completion of Patient Enrollment in Pivotal Antipsychotic Efficacy Study of ALKS 3831 for Schizophrenia 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47
List of Figure
List of Figures
Alkermes Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alkermes Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Alkermes Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Alkermes Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Alkermes Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Alkermes Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Civitas Therapeutics Raises USD55 Million in Series C Financing 11
Reset Therapeutics Enters into Co-Development Agreement with Alkermes 13
Biogen Enters into Licensing Agreement with Alkermes 14
Alkermes Enters into Licensing Agreement with Domain Therapeutics 15
Recro Pharma Acquires Certain Assets from Alkermes 16
Alkermes Plc, Key Competitors 18
Alkermes Plc, Key Employees 19
Alkermes Plc, Other Locations 21
Alkermes Plc, Subsidiaries 21
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.